4521
KAKEN PHARMACEUTICAL CO.,LTD.
科研製薬
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2022
76,034
Mar 2023
72,984
Mar 2024
72,044
Mar 2025
94,035
Mar 2026
76,871
Operating profit(million JPY)
Mar 2022
17,064
Mar 2023
7,998
Mar 2024
9,513
Mar 2025
21,034
Mar 2026
-899
Operating profit margin(%)
Mar 2022
22.44
Mar 2023
10.96
Mar 2024
13.2
Mar 2025
22.37
Mar 2026
-1.17
Profit before tax(million JPY)
Mar 2022
13,885
Mar 2023
6,817
Mar 2024
9,796
Mar 2025
19,435
Mar 2026
2,313
Profit(million JPY)
Mar 2022
9,549
Mar 2023
5,440
Mar 2024
8,025
Mar 2025
13,945
Mar 2026
2,144
Total assets(million JPY)
Mar 2022
165,181
Mar 2023
166,328
Mar 2024
171,623
Mar 2025
190,422
Mar 2026
178,217
Cash and cash equivalents(million JPY)
Mar 2022
74,625
Mar 2023
74,260
Mar 2024
65,325
Mar 2025
70,085
Mar 2026
50,705
Cash flows from operating activities(million JPY)
Mar 2022
13,336
Mar 2023
9,253
Mar 2024
2,577
Mar 2025
29,780
Mar 2026
-11,079
Cash flows from investing activities(million JPY)
Mar 2022
-7,888
Mar 2023
-2,627
Mar 2024
-5,854
Mar 2025
-19,650
Mar 2026
315
Cash flows from financing activities(million JPY)
Mar 2022
-8,129
Mar 2023
-6,990
Mar 2024
-5,658
Mar 2025
-5,369
Mar 2026
-8,841
Return on equity(%)
Mar 2022
7
Mar 2023
4
Mar 2024
5.7
Mar 2025
9.4
Mar 2026
1.4
Equity ratio(%)
Mar 2022
83.4
Mar 2023
81.9
Mar 2024
83.8
Mar 2025
80.2
Mar 2026
82.8
Earnings per share(JPY per share)
Mar 2022
251.43
Mar 2023
144.8
Mar 2024
212.67
Mar 2025
365.42
Mar 2026
56.57
Net assets per share(JPY per share)
Mar 2022
3,642.34
Mar 2023
3,636.17
Mar 2024
3,796.05
Mar 2025
3,974.47
Mar 2026
3,898.24
Dividend per share(JPY per share)
Mar 2022
150
Mar 2023
150
Mar 2024
150
Mar 2025
190
Mar 2026
190
Payout ratio(%)
Mar 2022
59.66
Mar 2023
103.59
Mar 2024
70.53
Mar 2025
51.99
Mar 2026
335.87
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.